Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended-Release Arbaclofen Reduces MS-related Spasticity

Publish date:: May 30, 2019

Key clinical point: Twice-daily, extended-release arbaclofen effectively reduces MS-related spasticity.

Major finding: Mean change in TNmAS-MAL was −2.90 with arbaclofen and −1.95 with placebo.

Study details: A multicenter, double-blind, parallel-group study of 341 adults with MS and spasticity.

Disclosures: The study did not have funding support. Dr. Kantor reported having received consulting fees from AbbVie, Actelion, Bayer, Biogen, Celgene, EMD Serono, Genentech/Roche, Mylan, Novartis, Osmotica, and Sanofi Genzyme.

Citation:

Kantor D et al. CMSC 2019, Abstract SXM07.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,